Floatz logo

Degarelix

Prostate Adenocarcinoma

Canadian Cancer Trials Groupprotein_peptidePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
73/ 100

Competitive context

88 Active assets in the Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
Nilutamide
SWOG Cancer Research Network
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB
Prednisone
Mayo Clinic
Phase 3BB
Goserelin
CancerCare Manitoba
Phase 3BB

View all 50 →

Same molecule, other indications

Degarelix is also rated in:

prostate carcinomaActive
BBB
Indicative · Phase 3
73 / 100
View asset →
prostate cancerActive
BBB
Indicative · Phase 4
72 / 100
View asset →
prostate neoplasmActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →